Prosthetic Heart Valves Market Report

Transcatheter heart valves are projected to have a significant market share by type of valve. This can be attributed to a variety of factors, including the high prevalence of heart valve diseases, the ease of implantation, an increase in the number of transcatheter heart valve surgery centres and patient population growth, which has resulted in a rise in the percentage of transcatheter aortic valve replacement procedures. According to the research published by the European Society of Cardiology, the prevalence of AS increases exponentially with age, with 0.2% in the 50-59-year age group, 1.3% in the 60-69-year age group, 3.9% in the 70-79-year age group and 9.8% in those aged 80-89 years. Transcatheter heart valves are utilised in patients suffering aortic valve stenosis and incompetence, hence demand for transcatheter heart valves is projected to increase rapidly. As a result of the aforementioned factors, the segment is projected to grow significantly during the forecast period.

Low levels of diagnostic testing, a lack of health awareness in developing nations, and the high cost of cardiac surgery are all factors that are restricting the growth of the prosthetic heart valve market. Similarly, mechanical heart valve failure/malfunction can develop after treatment for an artificial heart valve replacement/implantation in a variety of conditions.  Clots can dislocate from the prosthetic valve and go to the arteries and blood vessels that supply/reach the chambers of the heart (coronary arteries) or the brain (carotid arteries), resulting in a stroke or heart attack. Mechanical heart valves are more likely to cause thrombotic or thromboembolic complications. Medication and repair of heart valves are two of the many possible treatments for heart valve disease. Furthermore, heart valve repair can be performed through open-heart surgery or minimally invasive procedures. Heart valve replacement is only utilised as a last resort. This is emerging as a significant factor that is expected to hamper the growth of the prosthetic heart valve market over the forecast period.

Technology and materialization have contributed to the increased rate of market expansion due to organization’s dedication that results in better prosthetic heart valves and the patients’ experience. Currently, there is development of sophisticated artificial valves that can be biologically compatible, durable, and easy to implant. Technological breakthroughs such as, less invasive procedures, enhanced valve technologies and sophisticated TCVs are diversifying option and shortening healing times. For instance, in March 2023, Abbott released the notification regarding that it has received the approval of FDA with the introduction of EpicTM Max stented tissue valve for the condition of aortic regurgitation or aortic stenosis. It is a new generation of the Abbott’s Epic surgical valve, which started its long history in the 1980s. moreover, its design improves valve blood flow even further. Correspondingly, there have been regulatory milestones, with the United States Food and Drug Administration (FDA) last approving Edwards Lifesciences’ MITRIS RESILIA valve in March 2022. Originally, it’s a tissue valve replacement device which needs to be implanted especially in the mitral position of the heart.

The US has dominated a significant share of the market in North America. The high prevalence of heart valve problems, enhanced products, the number of heart valve replacement surgeries and the established healthcare infrastructure are the primary factors driving market expansion. As per the American College of Cardiology Foundation, the prevalence of valvular heart disorders (VHD) is increasing in the US, with more than 5 million Americans diagnosed each year, while up to 1.5 million individuals in the US suffer with aortic stenosis (AS). Several industry players are also adopting strategic initiatives, which are fuelling market expansion. For instance, Abbott announced that the US Food and Drug Administration (USFDA) has approved the company's Epic Plus & Epic Plus Supra Stented Tissue Valves to expand options for treatment for those with aortic or mitral valve disease. As a result of the aforementioned developments, the market is likely to expand throughout the forecast period.